Melanoma Mortality Risk Increases at 0.8-mm Thickness
Thin Melanoma: New Research Suggests Lowering Thickness Threshold for Staging
Study Finds Increased Risk of Death for Melanomas between 0.8mm and 1.0mm Thick
A groundbreaking new study published in JAMA Dermatology suggests that teh current staging system for melanoma may need to be revised. Researchers found that patients wiht melanomas measuring between 0.8mm and 1.0mm thick face a significantly higher risk of death compared to those with thinner tumors.
The study, which analyzed data from over 144,000 Australians diagnosed with thin (T1) primary invasive melanomas between 1982 and 2014, revealed a 20-year cumulative incidence of melanoma-related deaths of 6.3% for the entire cohort. However, this risk jumped to 11% for tumors measuring 0.8mm to 1.0mm thick, compared to just 4.6% for tumors thinner than 0.8mm.
“The findings of this large-scale population-based analysis suggest the separation of risk for patients with melanomas with a Breslow thickness above and below 0.8 mm,” the authors wrote.
Current Staging System May Need Revision
Currently, the American Joint Committee on Cancer (AJCC) staging system classifies melanomas as T1 if they are 1.0mm thick or less. This new research suggests that lowering the T1 threshold to 0.8mm could more accurately reflect the risk associated with these tumors.”These results suggest that a change of the T1 threshold from 1.0 mm to 0.8 mm should be considered when the AJCC staging system is next reviewed,” the authors added.
Survival Rates Remain High Overall
Despite the increased risk for those with tumors between 0.8mm and 1.0mm thick, the overall 20-year melanoma-specific survival rate for the entire cohort was 95.9%. This highlights the generally positive prognosis for patients diagnosed with thin melanomas.
Study Limitations
The study was based on registry data and did not include detailed facts about tumor characteristics or treatment modalities. Additionally, inaccuracies in reporting the cause of death may have influenced the results.Funding and Disclosures
The study was funded by Melanoma institute Australia and two grants from the Australian National Health and Medical Research Council (NHMRC).Several authors reported receiving grants or personal fees from or having ties with various sources, including NHMRC.
New Research Challenges Melanoma Staging System: Should we Reclassify Thin Tumors?
Newsdirectory3.com – A groundbreaking new study has ignited debate about how we classify and stage melanoma, the deadliest form of skin cancer.The research, published in JAMA Dermatology, suggests that the current system may be underestimating the risk posed by a specific range of “thin” melanomas.
For decades, physicians have relied on the American Joint Committee on Cancer (AJCC) staging system, which categorizes melanomas as T1 if their thickness (breslow depth) is 1.0 mm or less.But this new study, analyzing data from over 144,000 Australians diagnosed with thin melanomas between 1982 and 2014, revealed a crucial distinction.
The 20-year cumulative incidence of melanoma-related deaths was 6.3% for the entire cohort. However, this risk significantly increased to 11% for melanomas measuring between 0.8 mm and 1.0 mm thick, compared to a mere 4.6% for tumors thinner than 0.8 mm.
This finding has led researchers to propose a revision to the AJCC staging system, suggesting that the T1 threshold be lowered from 1.0 mm to 0.8 mm. This adjustment, they argue, would more accurately reflect the heightened risk associated with melanomas in that specific thickness range.
Despite this potential refinement to the staging system, the overall 20-year melanoma-specific survival rate for the entire cohort remained high at 95.9%. This underscores the generally positive prognosis for patients diagnosed with thin melanomas.
While promising, the study does have limitations. Since it relied on registry data, detailed details about tumor characteristics and treatment modalities was unavailable. Additionally, potential inaccuracies in reporting cause of death could have influenced the results.
Further research is needed to confirm these findings and explore their implications for clinical practice. Still, this study raises critically important questions about how we classify and manage thin melanomas, ultimately paving the way for more precise risk assessment and possibly improved patient outcomes.